Company Description
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John Celebi |
Contact Details
Address: 1405 Research Boulevard, Suite 125 Rockville, Maryland 20850 United States | |
| Phone | 240 243 8000 |
| Website | senseibio.com |
Stock Details
| Ticker Symbol | SNSE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1829802 |
| CUSIP Number | 81728A207 |
| ISIN Number | US81728A2078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher W. Gerry J.D. | President, General Counsel, Secretary and Director |
| Josiah Craver CPA | Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer |
| Anand Parikh Esq., J.D. | Chief Operating Officer and Director |
| Lora Pike | Vice President of Investor Relations and Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | 8-K | Current Report |
| Apr 29, 2026 | 144 | Filing |
| Apr 28, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |